<DOC>
	<DOCNO>NCT02368743</DOCNO>
	<brief_summary>This national , observational multicentre study aim establish picture real clinical practice management among patient treat Pentasa® , accord current therapeutic strategy ulcerative proctitis . This study able provide data patient ' health relate quality life , compliance efficacy real clinical practice .</brief_summary>
	<brief_title>QUality Life pAtients With Mild modeRate Active procTitis Treated mesalaZine ( Pentasa® )</brief_title>
	<detailed_description />
	<mesh_term>Proctitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Patient age 18 year old . Patient suffer mild moderate active proctitis ( MAYO score ≥ 3 ≤ 10 ) inclusion base clinical endoscopic finding within one month study inclusion Patient evidence endoscopic active proctitis ( Montreal classification E1 define involvement limited rectum , proximal extent inflammation distal rectosigmoid junction ) within one month study inclusion . Patient investigator decide start inclusion visit treatment current flare Pentasa® induce remission . Patient receive oral write information study , without objection use his/her personal data , sign write Informed Consent Form . Patient include interventional study assess treatment active proctitis Patient leave side , sigmoiditis pancolitis . Patient severe proctitis ( MAYO score ≥ 11 inclusion ) . Patient previously treat biologics . Patient treat immunosuppressive within 1 month study inclusion . Patient treat corticosteroid within 2 week study inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>